Verinurad is a selective urate reabsorption inhibitor developed for the treatment of hyperuricemia associated with gout. In pharmaceutical analysis, Verinurad reference standards are essential for characterizing… Read more
Verinurad is a selective urate reabsorption inhibitor developed for the treatment of hyperuricemia associated with gout. In pharmaceutical analysis, Verinurad reference standards are essential for characterizing the chemical profile of drug substances, supporting method validation, and conducting impurity profiling to meet regulatory quality standards. This category provides access to both the active pharmaceutical ingredient and related compounds required for precise analytical testing. Verinurad-d6, as a stable isotope labelled internal standard, is critical for laboratories performing mass spectrometry-based assays. By using these deuterated analogues, researchers can correct for matrix effects and variations during sample preparation, ensuring accurate quantification of the parent drug and its metabolites in biological matrices. These high-quality reference materials are indispensable tools for maintaining strict quality control and ensuring reliability throughout the drug development and clinical evaluation process.